Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hello Chevy and Ei
Midstates Petroleum Company, Inc. Schedules Second Quarter 2013 Earnings Release and Conference Call
Print
Alert
Midstates Pete Co. Com USD0.01 (NYSE:MPO)
Intraday Stock Chart
Today : Tuesday 16 July 2013
Click Here for more Midstates Pete Co. Com USD0.01 Charts.
Midstates Petroleum Company, Inc. (“Midstates” or the “Company”) (NYSE:MPO) announced today that its second quarter 2013 earnings release will be issued on Monday, August 5, 2013 after the close of trading on the NYSE. The Company will host a conference call to discuss second quarter results the following morning, Tuesday, August 6, 2013 at 10:00 a.m. Eastern time (9:00 a.m. Central time).
Participants may join the conference call by dialing (877) 645-4610 (for U.S. and Canada) or (707) 595-2723 (International). The conference call access code is 19946594 for all participants. To listen via live web cast, please visit the Investor Relations section of the Company's website, www.midstatespetroleum.com.
An audio replay of the conference call will be available approximately two hours after the conclusion of the call. The audio replay will remain available until Tuesday, August 13, 2013 and can be accessed by dialing (855) 859-2056 (for U.S. and Canada) or (404) 537-3406 (International). The conference call audio replay access code is 19946594 for all participants. The audio replay will also be available in the investor relations section of the Company’s website approximately two hours after the conclusion of the call and remain available for approximately 90 calendar days
got to love that dividend payed out today
going up, what a great 2 days
now were moving, up .10
7,390,226 on one trade, something was arranged
wow 7 mill traded and we are up a penney. :)
Top-Performer Profile—BNCCORP E-mail
The Diversified Market Strategist
By Vanessa Mambrino, Senior Consultant, Capital Performance Group LLC, Washington, DC, a firm providing advisory, planning, analytic, and project management support to the financial services industry.
BNCCORP, Inc., of Bismarck, ND, was founded in 1987 by Greg Cleveland, the current CEO, and Tracy Scott, who is now chairman. The bank has offices in North Dakota, Arizona, and Minnesota, and it became the #3-ranked non-subchapter-S corporation with total assets of between $100 million and $1 billion through a set of strategies as diverse as its markets.
In 1995, BNCCORP used the proceeds of its IPO to purchase several branches in North Dakota and capitalize a charter in Minneapolis. The branches in North Dakota turned out to be "right smack dab in the center" of the Bakken Oil Fields in the northwestern part of the state. This market has since become core growth corridor of BNCCORP's C&I lending division. Just over 52% of the holding company's loan portfolio is in either C&I or CRE loans, compared to 42% of the average top performing large non-S-corp's loan portfolio and 43% of the average non-S-corp's loan portfolio. The strong North Dakota economy has both good and not-so-good implications for 2013, says Cleveland. The C&I pipeline is "robust," however, "we're in a race to put on new loans before the old ones can be paid off," he says.
In 2001, BNCCORP chartered a bank in Arizona to enter the Phoenix market (all charters have since been consolidated). The bank has developed an SBA focus in Phoenix that has helped it to collect fee income via gains on loan sales. It should be noted that BNCCORP offers SBA products in all of its markets, but promotes them most heavily in Phoenix. "The SBA secondary markets have been very acquisitive and we have been seeing good premiums," notes Tim Franz, CFO. Revenue from SBA loan sales was $1.1 million in 2012.
In 2008, the bank began to invest in its mortgage banking unit. This line of business ramped up production in '08, '09, and '10 as BNCCORP built a network of producers and an online platform for originations. The bank now has mortgage-only offices throughout the Midwest and generated $1.1 billion in originations in 2012. Mortgage banking revenues were $29.6 million in 2012 compared to $11.3 million in 2011. Finally, the bank also benefited from a favorable litigation settlement in 2012.
In 2013, BNCCORP plans to expand its resources and its branch presence in North Dakota and to continue to constantly evaluate its business model and capital position. "All community banks have to answer the question: what do you want to be when you grow up? You can either sell or be aggressive on acquisitions to continue to remain independent," says Cleveland. In the meantime, both Cleveland and Franz believe that we can expect to see BNCCORP back among the top performers next year.
[This article was posted on June 6, 2013, on the website of ABA Banking Journal, www.ababj.com, and is copyright 2013 by the American Bankers Association.]
great article thanks for sharing
What u see in FNMA right now is called a value rush. Its pple wanting in before it goes to high because it'll bring incredible value later.
if you don't know what u are talking about, shut your mouth
Thanks for sharing Mr Chevy
A father today explained the shock tactics behind an advertising campaign he has launched to help find a cure for his six-year-old son’s muscle-wasting condition.
Harrison Smith was born with duchenne muscular dystrophy, which leads to loss of movement and, eventually, paralysis. Sufferers have a life-expectancy of around 25.
There is no treatment and no cure, but his father Alex has given up his job to dedicate himself to finding one. He hopes to achieve this by funding research through his charity Harrison’s Fund.
A campaign for the charity, launching today, features a picture of Mr Smith and Harrison and carries the slogan: “I wish my son had cancer”.
Explaining the advert, which appears on page 20 of the Standard, Mr Smith said: “For many people the notion of even wishing your child had cancer would be tough to understand, how could I wish a terrible disease on my own child? But the brutal truth is that there is a treatment in most cases. With duchenne there is no treatment, no cure, it’s 100 per cent fatal and at the moment one day he will be dead.”
Mr Smith, from Cobham, Surrey, who has another son William, four, with his wife Donna, 37, said when Harrison was first diagnosed in 2011, “the world turned upside down”. He said: “Coming to terms with a child that has a life-limiting condition, it’s not what we had mapped out for ourselves. We were also worried that we could have two sons with duchenne.
“I’m a very determined guy and I can’t accept being told, ‘Look after your son, give him the best life you can, he is going to die.’ I couldn’t accept that solution.”
As a result, he decided to give up his job in company branding to start a charity named after Harrison in a bid to find a practical solution for him and other sufferers.
Duchenne muscular dystrophy, which is caused by a genetic mutation in the dystrophin gene located on the X chromosome, affects around one in 3,500 boys in the UK.
Mr Smith said that at the moment Harrison has to attend Great Ormond Street Hospital regularly for analysis and has daily therapy at home.
He said his boy was not aware of the severity of his condition, which he refers to as “poorly muscles”.
In the first year the charity raised nearly £200,000 which is helping to fund research into treatment of the condition. Mr Smith is training to do an iron man competition in Barcelona and a team of 15 are going on a fundraising expedition to Everest.
BRND .0076 NOW
Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study Of Drug For Treatment Of Marburg Virus
Last update: 5/7/2013 8:30:43 AM
Got in this morning, iam with ya Ei
Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013
Sarepta Therapeutics, Inc. (MM) (NASDAQ:SRPT)
Intraday Stock Chart
Today : Friday 26 April 2013
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report first quarter financial results before the NASDAQ Global Market opens on Thursday, May 9, 2013. Subsequently, at 8:00 a.m., Eastern Time (5:00 a.m., Pacific Time), Chris Garabedian, Sarepta's President and CEO, will host a conference call to discuss first quarter financial results and to provide a corporate update.
The conference call may be accessed by dialing 800.446.2782 for domestic callers and 847.413.3235 for international callers. The passcode for the call is 34783365. Please specify to the operator that you would like to join the "Sarepta First Quarter Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at www.sareptatherapeutics.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.
Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013
Sarepta Therapeutics, Inc. (MM) (NASDAQ:SRPT)
Intraday Stock Chart
Today : Friday 26 April 2013
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report first quarter financial results before the NASDAQ Global Market opens on Thursday, May 9, 2013. Subsequently, at 8:00 a.m., Eastern Time (5:00 a.m., Pacific Time), Chris Garabedian, Sarepta's President and CEO, will host a conference call to discuss first quarter financial results and to provide a corporate update.
The conference call may be accessed by dialing 800.446.2782 for domestic callers and 847.413.3235 for international callers. The passcode for the call is 34783365. Please specify to the operator that you would like to join the "Sarepta First Quarter Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at www.sareptatherapeutics.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.
NEW YORK (TheStreet) -- It's been a little over a week since Sarepta Therapeutics(SRPT) announced the FDA asked for more information before deciding on whether or not to allow the company to seek accelerated approval for eteplirsen in Duchenne muscular dystrophy (DMD). This makes the coming "file or no file" announcement almost akin to an approval decision by FDA.
While I had originally assumed the FDA would allow Sarepta to file eteplirsen and then take a good, hard look at all the data, it now appears the FDA wants to make sure the first drug to take advantage of new accelerated approval provisions not be a bust. If the agency allows Sarepta to file early it means approval is almost guaranteed.
The Street is beginning to realize that eteplirsen's accelerated approval filing, if it happens, is akin to an approval. For Sarepta's stock, this should result in a massive reaction in one direction or the other as soon as the company discloses its eteplirsen filing plans this summer
i hope, but do u still think that :)
Merge Sets First Quarter 2013 Earnings Call
Print
Alert
Merge Healthcare Incorporated. (MM) (NASDAQ:MRGE)
Intraday Stock Chart
Today : Wednesday 17 April 2013
Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, announced today the scheduling of its first quarter 2013 earnings call, which will be held at 8:30 AM ET on Wednesday, May 1st.
The call will address first quarter results, followed by a business update on the company's market outlook and strategies for 2013. The first quarter 2013 earnings results for Merge will be published prior to the earnings call.
Participants may preregister for this teleconference at http://emsp.intellor.com?p=412375&do=register&t=8. Once the participant registers, a confirmation page will display dial-in numbers and a unique PIN, and the participant will also receive an email confirmation of this information.
A replay via the Internet or phone will be available after the call at http://www.merge.com/Company/Investors/Conference-Call-Info.aspx.
How low will we open, i say $34.00 then we bounce right back
A Proactive FDA Is Already Reviewing Sarepta's Muscular Dystrophy Drug
By Adam Feuerstein - 04/15/13 - 5:29 PM EDT
Tickers in this article: SRPT
CAMBRIDGE, Mass. (TheStreet) -- The U.S. Food and Drug Administration is actively reviewing the efficacy and safety of Sarepta Therapeutics' Duchenne muscular dystrophy drug eteplirsen even though the drug has not been formally filed for approval yet.
Weird, huh? But also good news for Sarepta. While investors have been obsessing over whether or not FDA will allow an eteplirsen accelerated approval, the agency is already reviewing the drug as if it was filed.
Why? Because FDA understands that a decision to allow Sarepta to file for accelerated approval filing means eteplirsen will be approved. What's going on with eteplirsen now at FDA is not a "file or don't file" decision, it's a mini review.
Read carefully Sarepta's announcement Monday because the evidence of an ongoing eteplirsen review is all there. FDA has asked the company to provide written summaries supporting the use of dystrophin as a surrogate endpoint for approval, as well as a discussion of clinical outcomes from the phase II study.
The FDA doesn't ask for this type of information from companies who haven't yet filed a drug for approval. Instead, these are the types of questions FDA asks of a drug sponsor during the review process.
So, what happens now? Sarepta puts together the data and submits it to FDA. The agency will then review the new data and make a final decision on accelerated approval. We don't know what the FDA will ultimately decide or when, but if the agency tells Sarepta, "Yes, you can file," then investors should interpret this as eteplirsen being approved.
Why is this good news, again? Because the FDA could have easily told Sarepta to come back with data from the planned phase III study. That would have told us FDA didn't believe the existing eteplirsen data.
I spoke briefly with Jenn McNary and Christine McSherry, DMD advocates who have met with top officials at FDA several times to lobby for eteplirsen's rapid approval. Both women are pleased with today's news because it shows the FDA is willing to work with Sarepta to get the drug to market as soon as possible.
"What we're seeing is a progressive, creative FDA," said McSherry, co-founder of the Duchenne Alliance.
"I feel pretty good about this," said McNary, whose son, Max, received eteplirsen in the phase II study. "This is what the FDA told us they'd do."
Sarepta shares were down 12% to $34.25 in Monday after-hours trading.
-- Reported by Adam Feuerstein in Boston.
did u listen CC , it will be fine
News not that bad, just bought more after hours, big bounce at open tomorrow
up $5.00 keep going
exploding
Sarepta Therapeutics Started at Buy by Canaccord Genuity >SRPT
Last update: 4/9/2013 7:56:43 AM
got to love it, I added on the dip the day before also, awesome
, lucky timing
awesome news this morning
Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study ...
PrintAlert
Sarepta Therapeutics, Inc. (MM) (NASDAQ:SRPT)
Intraday Stock Chart
Today : Friday 5 April 2013
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced updated data from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). Results at 74 weeks showed a continued stabilization of walking ability in eteplirsen-treated patients evaluable on the 6-minute walk test (6MWT). As previously reported, Study 202 met its primary endpoint of increased novel dystrophin as assessed by muscle biopsy at week 48 and is now in the long-term extension phase in which patients continue to be followed for safety and clinical outcomes. Eteplirsen is Sarepta's lead exon-skipping compound in development for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51.
After 74 weeks, patients in the 30 mg/kg and 50 mg/kg dose cohorts who were able to perform the 6MWT (modified Intent-to-Treat or mITT population; n=6) showed a statistically significant treatment benefit of 65.2 meters (p = 0.004) when compared to the placebo/delayed-treatment cohort (n=4). The eteplirsen-treated patients in the mITT population demonstrated less than a 5 percent decline (13.4 meters) from baseline in walking ability. After experiencing a substantial decline earlier in the study, the placebo/delayed-treatment cohort also demonstrated stabilization in walking ability from week 36 through 74, the period in which meaningful levels of dystrophin were likely produced, with a less than 10 meter decline over this timeframe.
"We are encouraged to see a continued stabilization of walking ability in patients treated with eteplirsen for nearly one and a half years," said Chris Garabedian, president and chief executive officer of Sarepta Therapeutics. "These data are particularly compelling when viewed in the context of published natural history studies, which showed substantial declines on the 6-minute walk test over this timeframe in a similar ambulatory DMD population. These results continue to support the potential of eteplirsen to be a major advance in the treatment of DMD in altering the course of this progressive and irreversible disease."
Through 74 weeks, eteplirsen was well tolerated and there were no clinically significant treatment-related adverse events, serious adverse events, hospitalizations or discontinuations. As previously reported at 62 weeks, one patient had a transient elevation of urine protein on a laboratory urine dipstick test, which resolved and resulted in no clinical symptoms. The patient continued treatment without interruption and remained free of proteinuria through week 74.
Across both the eteplirsen (mITT) and placebo/delayed-treatment cohorts, there is evidence of continued stabilization on clinical laboratory tests, echocardiogram, pulmonary function tests and muscle strength.
Summary of Additional 6MWT Analyses
Patients performed two 6MWT evaluations on consecutive days at time points coinciding with a muscle biopsy procedure at baseline and weeks 12, 24 and 48. All other evaluations were a single 6MWT. The pre-specified primary analysis included the maximum distance walked at those clinic visits where repeated tests were taken. Other analyses of the repeated 6MWT results assessed mean, minimum, and day 1 (first measure) scores. Results from these additional 6MWT analyses confirm the robust treatment effect observed in the primary analysis.
Summary of 6MWT: Eteplirsen (mITT) versus Placebo/Delayed-Treatment to Week 74*
----------------------------------------------------------------------------
Adjusted
Mean 6MWT Estimated
Analysis of Repeated Baseline Change Treatment Benefit
6MWT Values 6MWT from (Eteplirsen Minus P-Value
(meters) Baseline Placebo/delayed-
(meters) Tx)
----------------------------------------------------------------------------
Maximum Score =
Eteplirsen (n=6) 399.7 -13.4 65.2 m 0.004
----------------------------------------------
Maximum Score
Placebo/delayed-Tx (n=4) 394.5 -78.6
----------------------------------------------------------------------------
Mean Score =
Eteplirsen (n=6) 388.6 -2.2 62.4 m 0.007
----------------------------------------------
Mean Score
Placebo/delayed-Tx (n=4) 380.3 -64.6
----------------------------------------------------------------------------
Minimum Score =
Eteplirsen (n=6) 377.5 +9.0 59.6 m 0.015
----------------------------------------------
Minimum Score
Placebo/delayed-Tx (n=4) 366.0 -50.6
----------------------------------------------------------------------------
Day 1 Score =
Eteplirsen (n=6) 379.7 +6.6 62.2 m 0.013
----------------------------------------------
Day 1 Score
Placebo/delayed-Tx (n=4) 371.5 -55.6
----------------------------------------------------------------------------
*All analyses are based on a Mixed Model Repeated Measures test.
Jerry R. Mendell, M.D., Director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children's Hospital and principal investigator of the Phase IIb study, will present these data in an oral presentation at the Muscular Dystrophy Association Scientific Conference on Tuesday, April 23 at 4:05 p.m. EDT in Washington, D.C. Dr. Mendell's presentation will be posted on the Sarepta website in the "Events & Presentations" section after the session is completed.
About the Phase IIb Eteplirsen Program (Studies 201 and 202)
Study 201 was a randomized, double-blind, placebo-controlled clinical study conducted at Nationwide Children's Hospital in Columbus, Ohio. Twelve boys aged 7-13 years with a confirmed genotype amenable to treatment with an exon-51 skipping drug were randomized to one of three cohorts: 30 mg/kg (n=4), 50 mg/kg (n=4), and placebo/delayed treatment (n=4). Eteplirsen and placebo were administered weekly by intravenous infusion.
At Week 25, all patients rolled over to Study 202, a long-term open-label extension study, and placebo-treated patients initiated eteplirsen treatment at 30 mg/kg (n=2) or 50 mg/kg (n=2).
The primary efficacy endpoint in Study 201 and Study 202 was the increase in novel dystrophin as assessed by muscle biopsy at weeks 12 and 24 and at week 48, respectively. The primary clinical endpoint was the 6MWT, a well-accepted measure of ambulation and clinical function in DMD. Long-term follow up in Study 202 continues to evaluate safety and clinical outcomes including the 6MWT every 12 weeks.
About the 6-Minute Walk Test (6MWT)
The 6-minute walk test (6MWT) was developed as an integrated assessment of cardiac, respiratory, circulatory, and muscular capacity (American Thoracic Society 2002) for use in clinical trials of various cardiac and pulmonary conditions. In recent years the 6MWT has been adapted to evaluate functional capacity in neuromuscular diseases and has served as the basis for regulatory approval of a number of drugs for rare diseases, with mean changes in the 6MWT ranging from 28 to 44 meters (Rubin 2002, Wraith 2004, Muenzer 2006). Additionally, published data from longitudinal natural history studies assessing dystrophinopathy, a disease continuum comprised of DMD and Becker muscular dystrophy, support the utility of the 6MWT as a clinically meaningful endpoint (McDonald 2010) in DMD. These data show that boys with DMD experience a significant decline in walking ability compared to healthy boys over one year, suggesting that slowing the loss of walking ability is a major treatment goal.
About the Statistical Methodology and the Modified Intent-to-Treat (mITT) Population
The Mixed Model Repeated Measures (MMRM) test was used for all statistical analyses of the 6MWT results, including for all subgroups. Analysis of Covariance (ANCOVA) for ranked data was used when the assumptions of normality of the dependent variable (the change in 6MWT distance from baseline) were violated. Baseline 6MWT scores and duration since DMD diagnosis were included as covariates.
The mITT population used in the 6MWT analyses consisted of 10 of the 12 enrolled patients, including 4 patients in the 50 mg/kg cohort, 2 patients in the 30 mg/kg cohort and 4 patients in the placebo/delayed-treatment cohort. Two patients in the 30 mg/kg cohort showed rapid disease progression upon enrollment and lost ambulation by week 24, and thus were excluded.
About Duchenne Muscular Dystrophy
DMD is an X-linked rare, degenerative neuromuscular disorder causing severe progressive muscle loss and premature death. One of the most common fatal genetic disorders, DMD affects approximately one in every 3,500 boys worldwide. A devastating and incurable muscle-wasting disease, DMD is associated with specific errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Progressive muscle weakness eventually spreads to the arms, neck and other areas. Eventually, this progresses to complete paralysis and increasing difficulty in breathing due to respiratory muscle dysfunction requiring ventilation support, as well as cardiac dysfunction leading to heart failure. The condition is terminal, and death usually occurs before the age of 30.
About Sarepta's Proprietary Exon-Skipping Platform Technology
Eteplirsen is Sarepta's lead drug candidate that is designed to address the underlying cause of DMD by enabling the production of a functional dystrophin protein. Data from clinical studies of eteplirsen in DMD patients have demonstrated a broadly favorable safety and tolerability profile and restoration of dystrophin protein expression.
Eteplirsen uses Sarepta's novel phosphorodiamidate morpholino oligomer (PMO)-based chemistry and proprietary exon-skipping technology to skip exon 51 of the dystrophin gene enabling the repair of specific genetic mutations that affect approximately 13 percent of the total DMD population. By skipping exon 51, eteplirsen may restore the gene's ability to make a shorter, but still functional, form of dystrophin from messenger RNA, or mRNA. Promoting the synthesis of a truncated dystrophin protein is intended to improve, stabilize or significantly slow the disease process and prolong and improve the quality of life for patients with DMD.
Sarepta is also developing other PMO-based exon-skipping drug candidates intended to treat additional patients with DMD.
About Sarepta Therapeutics
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.
Forward-Looking Statements and Information
This press release contains forward-looking statements. These forward-looking statements generally can be identified by use of words such as "believes or belief," "anticipates," "plans," "expects," "will," "intends," "potential," "possible," "advance" and similar expressions. These forward-looking statements include statements about the development of eteplirsen and its efficacy, potency and utility in the treatment of DMD and the potential for the creation of novel dystrophin to lead to significant clinical benefit over a longer course of treatment.
Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: subsequent clinical trials may fail to demonstrate the safety and efficacy of eteplirsen or replicate results; treatment of patients with DMD using eteplirsen over a longer duration may not lead to significant clinical benefit; any of Sarepta's drug candidates, including eteplirsen, may fail in development, may not receive required regulatory approvals, or may not become commercially viable due to delays or other reasons; and those identified under the heading "Risk Factors" in Sarepta's Annual Report on Form 10-K for the full year ended December 31, 2012, and filed with the Securities and Exchange Commission.
Any of the foregoing risks could materially and adversely affect Sarepta's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the Company's filings with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
Wow, what are we to make on the gap, $2.66 bid to $5.00 ask, cant wait to see if they hit that ask
WOW got to be a first, jim cramer talks about last night and the stock tanks $2.40 right now, hmmmmmm
LOOKING GOOD EI, LOOKIN GOOD
I like it, little upward movement, now a little volume and we shall really move
so what
the last week has been fantastic
same proble here
no one will have the balls, all freakin talk
guess its the hype for 60 mins